DaVita® Medical Insights

COVID-19 UPDATES

The health and safety of our patients and teammates is our top priority. We are keeping a close eye on this situation and reinforcing the extensive infection control practices already in place to protect them. Click here to find videos and additional resources.

Study: Reduced Lengths of Stay for Patients with End Stage Kidney Disease Treated by DaVita Hospital Services

Patients with end stage kidney disease (ESKD) spend on average approximately 11 days in the hospital each year. Although dialysis is a moderate risk procedure for patients with ESKD who are admitted to hospitals, complications such as infections may affect patient outcomes, including quality of life, and subsequently lengthen hospital stay duration. In our efforts to continuously improve clinical outcomes and experience for our patients receiving inpatient dialysis, DaVita Hospital Services measured mean length of stay (LOS) for our partner hospitals as compared with other short-term acute care hospitals.

In this study approximately 500,000 ESKD patient admissions from January 2017 through September 2019 across DaVita partner hospitals and other acute care hospitals were analyzed. Both hospital groups had similar reasons for admission and patient demographics.

The results demonstrated that DaVita partner hospitals had a 3.85% to 3.95% lower mean LOS (averaged over all months) compared to all other hospitals studied (see graph below). This means that for every 30 hospitalizations, Hospital Services patients are spending 10 fewer days in the hospital.

The results also demonstrated that DaVita partner hospitals outperformed the others in terms of LOS, regardless of the following three key parameters:

  • Hospital type (academic institutions or level 1 trauma centers)
  • Size of hospital (more than 400 beds or 400 beds or fewer)
  • Source of hemodialysis (insourced with hospitals providing their own dialysis or outsourced)

Shorter hospital stays not only improve quality of life for dialysis patients but increase capacity and reduce costs for the hospital, as well.

For more information on other ways hospitals could benefit from partnering with DaVita, read the case study on the DaVita web site here or email hospitals@davita.com

David L. Mahoney, MD

David L. Mahoney, MD

David L. Mahoney, MD, is chief medical officer of DaVita Hospital Services Group. Dr. Mahoney, a trained interventional nephrologist, joined DaVita in 2017 as CMO for DaVita's vascular access care business. Prior to his current role, he was in private practice for more than 20 years in the Washington, DC, area, where he was also the medical director of a DaVita Kidney Care chronic dialysis facility, a hospital acute dialysis service and his practice's vascular access center. From 2013 to 2017 he served as a group medical director for DaVita Kidney Care. Dr. Mahoney received his undergraduate degree in biochemical sciences from Harvard College and his medical degree from Boston University School of Medicine. He completed residency and fellowship training at Walter Reed Army Medical Center in Washington, DC. He served for 10 years on active duty as an Army physician before entering private practice in 1995. Dr. Mahoney and his wife live in Washington, DC and have three adult children.